Literature DB >> 8519897

Enhanced replication of orbiviruses in bovine testicle cells infected with bovine viral diarrhoea virus.

S Nakamura1, T Shimazaki, K Sakamoto, A Fukusho, Y Inoue, N Ogawa.   

Abstract

Bovine testicle (BT) cells infected with non-cytopathogenic (NCP) bovine viral diarrhoea virus (BVDV) developed cytopathogenic effect (CPE) after superinfection with 7 Orbiviruses, whereas no CPE was induced by them in the absence of NCP BVDV infection. The CPE was accompanied by the enhanced replication of Orbiviruses. Seven of 10 strains of NCP BVDV induced the enhanced replication of Ibaraki virus, a member of Orbivirus. These 7 strains of NCP BVDV were END phenomenon positive. In contrast, the absence of CPE and the suppression of growth of Ibaraki virus were seen in BT cells infected with the other 3 strains which were END phenomenon negative. The END phenomenon negative viruses were different markedly from the END phenomenon positive viruses with respect to interactions with Orbivirus. The mechanism of the enhanced replication of Orbivirus seems to be explained with the suppression by the END phenomenon positive NCP BVDV to the interferon production of Orbivirus in BT cells.

Entities:  

Mesh:

Year:  1995        PMID: 8519897     DOI: 10.1292/jvms.57.677

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  8 in total

1.  Alpha/beta and gamma interferons are induced by infection with noncytopathic bovine viral diarrhea virus in vivo.

Authors:  B Charleston; L S Brackenbury; B V Carr; M D Fray; J C Hope; C J Howard; W I Morrison
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Identification of a cell population that produces alpha/beta interferon in vitro and in vivo in response to noncytopathic bovine viral diarrhea virus.

Authors:  L S Brackenbury; B V Carr; Z Stamataki; H Prentice; E A Lefevre; C J Howard; B Charleston
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Innate immune responses of calves during transient infection with a noncytopathic strain of bovine viral diarrhea virus.

Authors:  Doris Müller-Doblies; Adrian Arquint; Patrick Schaller; Peter M H Heegaard; Monika Hilbe; Sarah Albini; Carlos Abril; Kurt Tobler; Felix Ehrensperger; Ernst Peterhans; Mathias Ackermann; Alfred Metzler
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

4.  Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus.

Authors:  David Durantel; Sandra Carrouée-Durantel; Norica Branza-Nichita; Raymond A Dwek; Nicole Zitzmann
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  Inhibition of beta interferon transcription by noncytopathogenic bovine viral diarrhea virus is through an interferon regulatory factor 3-dependent mechanism.

Authors:  Susan J Baigent; Gang Zhang; Martin D Fray; Helen Flick-Smith; Stephen Goodbourn; John W McCauley
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Classical swine fever virus interferes with cellular antiviral defense: evidence for a novel function of N(pro).

Authors:  Nicolas Ruggli; Jon-Duri Tratschin; Matthias Schweizer; Kenneth C McCullough; Martin A Hofmann; Artur Summerfield
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response.

Authors:  A Hayman; S Comely; A Lackenby; L C S Hartgroves; S Goodbourn; J W McCauley; W S Barclay
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

8.  Analysis of a pair of END+ and END- viruses derived from the same bovine viral diarrhea virus stock reveals the amino acid determinants in Npro responsible for inhibition of type I interferon production.

Authors:  Takashi Kozasa; Yuri Abe; Kazuya Mitsuhashi; Tomokazu Tamura; Hiroshi Aoki; Masatoshi Ishimaru; Shigeyuki Nakamura; Masatoshi Okamatsu; Hiroshi Kida; Yoshihiro Sakoda
Journal:  J Vet Med Sci       Date:  2014-12-28       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.